Prevention of end-stage kidney disease and kidney disease related morbidities and mortality is a key objective in the research on chronic kidney disease (CKD). It is important to identify biomarkers or factors involved in pathophysiology if CKD. To achieve this, samples of different types (blood, buffycoat, urine, dialysate, faeces, nails) of patients in different stages of CKD have been stored in the registered biobank: "Biobank Kidney Ghent" with medical manager W. Van Biesen and operational manager G. Glorieux. The routinely collected clinical and outcome data is maintained in parallel in a central secure pseudonymised datafile (F Verbeke). In collaboration with D. De Bacquer, the predictive value of new biomarkers (uremic toxins, markers for endothelial damage), proteome and metabolic profiles for cardiovascular and survival outcome are studied. This will lead to clinically relevant tools to support the treatment of patients with CKD. These samples are also available to other researchers with a specific research questions.